Shares of Sun Pharmaceuticals Industries (Sun Pharma) jumped 6% to ₹1,709.25 on the Bombay Stock Exchange (BSE) after the company announced its acquisition of Organon & Co. for $14 per share, totaling $11.75 billion. This acquisition aligns with Sun Pharma's strategy to enhance its Innovative Medicines business and enter the biosimilars market as a top global player. Despite the positive market reaction, Sun Pharma's stock has underperformed in the past month, falling 5% compared to a 0.6% increase in the BSE Sensex. The deal is expected to close in early 2027, subject to regulatory and stockholder approvals. Analysts from ICICI Securities have expressed concerns about the acquisition's strategic challenges, including competitive pressures facing Organon and the assumption of $8.6 billion in debt, which could affect the combined company's financial outlook. The anticipated combined revenues post-acquisition are estimated at $12.4 billion, with the innovative portfolio contributing 27%.